In this issue:
- Nivolumab + ipilimumab in MSH mCRC
- Post-colonoscopy CRC
- Diet-wide analyses for risk of CRC
- Single-round performance of CRC screening
- Optimal stopping ages for CRC screening
- Combining cetuximab with traditional chemotherapy
- Quality-adjusted survival with fruquintinib in mCRC
- Health-related quality of life associated with fruquintinib
- Disappearing colorectal liver metastases
- Total neoadjuvant therapy vs preoperative chemoradiotherapy
Please login below to download this issue (PDF)